The post-traumatic stress disorder (PTSD) therapeutics market is a crucial segment of the pharmaceutical industry. This industry deals in the manufacturing and distribution of PTSD therapies across the world. These drugs are manufactured using selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), herbs and nutraceuticals and some others. These medicines help in increasing the levels of several neurotransmitters in the brain to treat depression and other mental disorders. This market is likely to rise significantly with the growth of the pharmaceutical sector across the world.
The rising incidences of anxiety disorders among middle-aged men, along with increased awareness of mental health across the world, have boosted the market growth. Also, the growing demand for antidepressants and antipsychotic drugs from the psychiatric sector has contributed positively to industrial growth. Moreover, the availability of these therapies in hospital pharmacies and retail pharmacies, along with the rise in the number of e-commerce platforms that deal in PTSD therapeutics, is anticipated to boost the growth of the post-traumatic stress disorder (PTSD) therapeutics market.
The advancements in brain imaging technology, along with the rising emphasis on ketamine and psilocybin for PTSD treatment areas, are expected to create ample growth opportunities for the market players in the future. In September 2024, Tilray Medical launched Redecan Cannabis. Redecan Cannabis is found effective for the treatment of post-traumatic stress disorder (PTSD).
Download
Order Databook
Actionable Solutions
